Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)

NCT01443845 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01443845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01443845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2011
Completion date
January 31, 2016
Enrollment
2,354 (actual)
Sites
338

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive airway disease, chronic obstructive lung diseases, copd, copd exacerbation, lung diseases, pulmonary disease, respiratory disorders